Introduction {#sec1-1}
============

Ayurveda recognized, *Prameha* as a disease entity in distant past. Among several health problems *Prameha*, is considered as one of the arch enemy of the mankind. *Prameha* comprises a number of diseases with various physical and chemical changes in urine. The manifestation of the disease is described as "*Prabhutavilmutrata*," which means frequent and copious urine with turbidity.\[[@ref1][@ref2]\] It is also believed that, if not cured or treated properly in due course of time, *Prameha* changes in *Madhumeha*, which is very similar to diabetes mellitus, the most debilitating disease.\[[@ref3]\]

Diabetes mellitus is a metabolic disorder characterized by polyurea, polydipsia, hyperglycemia, glycosuria, and generalized weakness may be associated with weight loss. This is the disease that affects every tissue and every organ of the body and is responsible for significant morbidity, reduced life expectancy, and diminished quality of life. It has been seen that there is no any organ or system spared from the diabetic complications, such as nephropathy, neuropathy, retinopathy, and so on. So there is a need for effective drugs for controlling Diabetes and preventing undesirable complications.

Although the introduction of many oral hypoglycemic agents and insulin in modern medical science have great importance in the management of Diabetes, the hazardous effects of these drugs after long term use are incurable or proves many times fatal, hence an ideal therapy is still obscure. Ayurvedic management of Diabetes aims not only to achieve a euglycemic state but also to treat the root cause of disease. There are many medicinal plants mentioned in Ayurvedic texts, particularly in Nighantus having *Pramehahara* property. In the present work, the drug "*Rishyagandha*" (*Withania coagulans*) has been used for the management of *Prameha*. The selected trial drug *Rishyagandha* is mentioned in *Charaka Samhita* in *Brihaniya Mahakashaya*\[[@ref4]\] and *Madhur a skandha dravya*.\[[@ref5]\]

Aims and objectives {#sec2-1}
-------------------

Clinical evaluation of *Rishyagandha* fruit powder in the management of *Prameha*.

Drug review {#sec2-2}
-----------

The drug *Rishyagandha* (*W. coagulans* Dunal, family Solanaceae) is mentioned in Charaka samhita in *Brihaniya Mahakashaya* and *Madhur skandha dravya*. In northern India, its fruits are used in the treatment of *Prameha*.\[[@ref6]\] This plant has the property of coagulating milk, and has been used for preparing a vegetable rennet ferment for making cheese.

Preparation of drug and dosage {#sec2-3}
------------------------------

Trial drug preparation consists of *Rishyagandha* fruit powder in dose of 10 g daily in 2 divided doses.

Materials and Methods {#sec1-2}
=====================

A series of 53 patients with Diabetes Mellitus were selected from the Outpatient Department (OPD) and Inpatient Department (IPD) of the Department of Kaya Chikitsa, S.S. Hospital, B.H.U. Most of these cases were known diabetics while some were diagnosed for the first time when they came with other complaints.

Inclusion criteria {#sec2-4}
------------------

Symptoms of diabetes along with random blood glucose concentration ≥11.1 mmol/L (200 mg/dL).Fasting plasma glucose ≥7.0 mmol/L (126 mg/dL).Two-hour plasma glucose ≥11.1 mmol/L (200 mg/dL) during an oral glucose tolerance test.\[[@ref7]\]

Exclusion criteria {#sec2-5}
------------------

All type 1 Diabetes Mellitus cases.Cases with complications of the disease or having other associated diseases.Cases were excluded from the study which developed complications during the study.

Grouping of the patients {#sec2-6}
------------------------

Registered patients were into 3

Group A: Patients who were taking no drug before initiation of therapy, were kept on trial drug.Group B: Patients were permitted the OHA with unmodified dose which they were taking before initiation of therapy were treated as the control group.Group C: Patients were given a trial drug with the ongoing OHA in the same dose whatever they were taking before the initiation of the treatment.

Criteria to assess the effect of trial drugs {#sec2-7}
--------------------------------------------

All the selected patients have been advised to come for the follow-up for 3 months at regular intervals of 1 month. The clinical grades were decided as follows:
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Objective assessment {#sec2-8}
--------------------

Fasting and postprandial blood sugar have been done in each followup to the completion of study (3 months).Routine urine examination in each follow-up.Lipid profile in selected cases before and after completion of treatment.Regular checkup of body weight in each follow-up.

Observation and Results {#sec1-3}
=======================

The observations and results in the study are made on the basis of demographic, constitutional, and clinical profiles of 53 patients having type II diabetes mellitus. Out of 53 patients, 13 patients dropped out the treatment \[[Table 1](#T1){ref-type="table"}\].

###### 

Therapy wise details of the groups
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Maximum cases reported in the study were male (72%). Maximum cases (36%) were of the age group 40--50 years. Most cases (about 77%) were from middle socioeconomic group and maximum cases (about 34%) were businessmen. 32% cases registered were from above graduation group. The study revealed that higher incidence was found in urban dwellers (58%), and incidence in dietary habits was found more in persons with mixed diet (51%). Regarding incidence in physical activities, more patients are mild active (49%). Maximum cases found (53%) in the study were obese (body mass index \>30 kg/m^2^). About 53% cases belonged to *Tamasa Prakriti*, and about 43% cases were belonging to *kapha Pittaja prakriti*. Maximum cases were reported with a positive family history (64%), and the duration of illness was more than 5 years in maximum cases (about 40%).

About 82% cases were presented with weakness followed by about 70% with tingling or burning sensation followed by 62% with polyurea. About 43% cases registered with complaints of joint pain and 32% cases with weight loss. Polyphagia was found in 28% cases and polydipsia in 21% cases, least number of cases (9%) were registered with the complaints of loss of libido.

Effect of treatment {#sec2-9}
-------------------

As per paired *t* test all the 3 groups (group A, B, and C) showed statistically significant results in the above-mentioned subjective and objective parameters.

Group A showed highly significant relief on polyurea (56.07%), polyphagia (82.50%), weakness (66.67%), burning and tingling sensation (62.99%) and joints pain (82.50%). Group B showed significant result on polyurea (33.33%), polyphagia (78.57%), weakness (58.45%), burning and tingling sensation (21.36%), and joints pain (30.12%). Group C also showed highly significant relief on polyurea (63.88%), polyphagia (65.21%), weakness (52.05%), burning and tingling sensation (41.30%), and joints pain (50.00%) \[Tables [2](#T2){ref-type="table"}--[6](#T6){ref-type="table"}\]. Effect on blood biochemical parameters of the treatments in all the groups were placed in Tables [6](#T6){ref-type="table"}--[13](#T13){ref-type="table"}\].

###### 

Mean change in polyurea
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###### 

Mean change in polyphagia
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###### 

Mean change in weakness
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###### 

Mean change in burning and tingling sensation
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###### 

Mean change in joint pain
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###### 

Effect of treatment on fasting blood sugar
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###### 

Effect of treatment on postprandial blood sugar

![](Ayu-32-507-g009)

###### 

Effect of treatment on serum cholesterol
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###### 

Effect of treatment on serum triglyceride
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###### 

Effect of treatment on serum HDL
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###### 

Effect of treatment on blood urea
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###### 

Effect of treatment on serum creatinine
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Probable mode of action of drugs {#sec2-10}
--------------------------------

The plant *Rishyagandha* (*W. coagulans* Dunal) is described in *Charaka Samhita* in "*Brihaniya Mahakashaya*"(a collection of drugs, which increases body mass) and "*Madhur Skandha Dravya*".

*Charaka* has described two types of therapies for *Prameha*, that is, *Sambrihana* (process which increases body mass), for *krisha* and *dourbala pramehi* and *Samshodhana* (a type of therapy which eliminates impurities from body) for *sthula* and *balvan pramehi*.\[[@ref8]\] So in *krisha* and *dourbala patient*, *Rishyagandha* improves the quality of *dhatu* production, promotes the *Oja* formation, and curesthe *prameha* by its *brimhana* property.

In *sthula pramehi*, trial drug acts by the virtue of *Dravya prabhava* (effect of drug). By *dravya prabhava*, it acts on the pathogenesis of *Madhumeha* and breaks down the continuity of *Prameha*.

Conclusion {#sec1-4}
==========

It can be concluded from the present study that *Rishyagandha* fruit powder can be used effectively for a long-term in the treatment of *Prameha* (Type II Diabetes Mellitus) without any side effects.
